The effect of oral selenium administration on the treatment of uncomplicated neonatal jaundice through a randomized clinical trial.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250829067032N1

Enrollment

105

Registered

2026-01-30

Start date

2025-09-23

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperbilirubinemia. Neonatal jaundice, unspecified

Interventions

Intervention 1: Intervention group: High-dose treatment group: This group of patients is given oral selenium at a dose of 3 micrograms per body weight daily. The treatment continues for 3 to 5 days. R

Eligibility

Sex/Gender

All

Age

1 Days to 30 Days

Inclusion criteria

Inclusion criteria: neonatal hyperbilirubinemia term no complication

Exclusion criteria

Exclusion criteria: Neonatal jaundice within the range of blood exchange Parental disapproval

Design outcomes

Primary

Measure	Time frame
Bilirubin. Timepoint: Every 12 hours. Method of measurement: -Laboratory.;Duration of hospitalization. Timepoint: After discharge. Method of measurement: day.;Complication of hospitalization. Timepoint: daily. Method of measurement: physical exam and history.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Bayati

Jahrom University of Medical Sciences

mehdibayati73@gmail.com+98 937 572 3897

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026